Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Goetz

Showing results (231-240 of 265) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2020
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast CancerSiddhartha Yadav, Chunling Hu, Steven N Hart, et al.
Nature Communications|April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancerJodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast CancerMatthew P Goetz, Vera J Suman, Joel M Reid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083George Somlo, Paul H Frankel, Banu K Arun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast CancerCynthia X Ma, Ron Bose, Feng Gao, et al.
NPJ Breast Cancer|February 18, 2022
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancerKirsten G M Aspros, Jodi M Carter, Tanya L Hoskin, et al.
JAMA Network Open|November 3, 2025
Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer IndexRuth M O'Regan, Yue Ren, Yi Zhang, et al.
Breast Cancer Research : BCR|December 8, 2017
Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer studyJia Yu, Bo Qin, Ann M Moyer, et al.
Blood|January 28, 2021
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repairJithma P Abeykoon, Xiaosheng Wu, Kevin E Nowakowski, et al.
Breast Cancer Research : BCR|March 26, 2021
Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer studyJia Yu, Bo Qin, Ann M Moyer, et al.
Pageof 27

Showing results (231-240 of 265) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2020
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast CancerSiddhartha Yadav, Chunling Hu, Steven N Hart, et al.
Nature Communications|April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancerJodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast CancerMatthew P Goetz, Vera J Suman, Joel M Reid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083George Somlo, Paul H Frankel, Banu K Arun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast CancerCynthia X Ma, Ron Bose, Feng Gao, et al.
NPJ Breast Cancer|February 18, 2022
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancerKirsten G M Aspros, Jodi M Carter, Tanya L Hoskin, et al.
JAMA Network Open|November 3, 2025
Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer IndexRuth M O'Regan, Yue Ren, Yi Zhang, et al.
Breast Cancer Research : BCR|December 8, 2017
Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer studyJia Yu, Bo Qin, Ann M Moyer, et al.
Blood|January 28, 2021
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repairJithma P Abeykoon, Xiaosheng Wu, Kevin E Nowakowski, et al.
Breast Cancer Research : BCR|March 26, 2021
Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer studyJia Yu, Bo Qin, Ann M Moyer, et al.
Pageof 27